Bavdegalutamide
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| drug_name = Bavdegalutamide
| INN =
| type =
| image = Bavdegalutamide.svg
| width =
| alt =
| caption =
| image2 =
| width2 =
| alt2 =
| caption2 =
| imageL =
| widthL =
| altL =
| imageR =
| widthR =
| altR =
| captionLR =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration =
| class =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 2222112-77-6
| CAS_supplemental =
| PubChem = 134414307
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank = DB19032
| ChemSpiderID = 110415899
| UNII = H6NYM0V650
| KEGG = D12316
| ChEBI =
| ChEMBL = 4862963
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = ARV-110
| IUPAC_name = N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide
| chemical_formula =
| C = 41 | H = 43 | Cl = 1 | F = 1 | N = 9 | O = 6
| molecular_weight =
| SMILES = C1CC(CCC1NC(=O)C2=NN=C(C=C2)N3CCC(CC3)CN4CCN(CC4)C5=C(C=C6C(=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)F)OC8=CC(=C(C=C8)C#N)Cl
| Jmol =
| StdInChI = InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)
| StdInChI_comment =
| StdInChIKey = CLCTZVRHDOAUGJ-UHFFFAOYSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader.{{Cite web | work = PubChem |title=Bavdegalutamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/Bavdegalutamide |access-date=2024-10-31 | publisher = U.S. National Library of Medicine |language=en}} It is being developed to treat metastatic castration-resistant prostate cancer.{{Cite journal | vauthors = Shore ND, Shen J, Devitt ME, Lu H, Alicea J, Parameswaran J, Chirnomas D, Gao X, McKean M |date= June 2022 |title=Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer. |url=https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5106 |journal=Journal of Clinical Oncology |language=en |volume=40 |issue=16_suppl |pages=TPS5106 |doi=10.1200/JCO.2022.40.16_suppl.TPS5106 |issn=0732-183X}}{{cite web | title = Bavdegalutamide - Arvinas| url = https://adisinsight.springer.com/drugs/800054393 | work = AdisInsight | publisher = Springer Nature Switzerland AG }}{{cite journal | vauthors = Jia X, Han X | title = Targeting androgen receptor degradation with PROTACs from bench to bedside | journal = Biomedicine & Pharmacotherapy | volume = 158 | issue = | pages = 114112 | date = February 2023 | pmid = 36508999 | doi = 10.1016/j.biopha.2022.114112 | doi-access = free }}